Albuterol and Ipratropium Oral Inhalation
Albuterol and ipratropium is a combination of two bronchodilators (medicines that open the airways) used to treat bronchospasm in chronic obstructive pulmonary disease (COPD), available as an inhaler and as a nebulizer solution.
🧬 Where this information comes from
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 18 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Albuterol and ipratropium combines two bronchodilators (airway openers) for COPD, albuterol relaxing the airway muscles and ipratropium blocking acetylcholine, a chemical that tightens them, and it is a familiar add-on when one bronchodilator is not enough, on the market since about 2007 and available generically. Most people tolerate it well, and the usual complaints are cough, headache, or a stuffy nose and sore throat. Stop it and get help right away if your breathing worsens after a dose (airways tightening instead of opening) or you have an allergic reaction. Never take extra doses, because deaths have been reported with overuse, and get prompt advice if your usual dose stops working.
Clinical pearls
- Keep the spray or mist out of your eyes, because ipratropium can raise eye pressure and worsen narrow-angle glaucoma.
- Ipratropium can make urine hard to pass, a real concern for men with an enlarged prostate or a blocked bladder neck.
- Tell your prescriber about any other inhalers, since adding more albuterol-type or anticholinergic medicine stacks the side effects.
- Diuretics (water pills) can deepen albuterol's potassium-lowering effect, and beta-blockers can blunt its airway-opening effect.
Patient Information Guide A plain-language walkthrough of Albuterol and Ipratropium Oral Inhalation, written from its FDA label.
What Albuterol and Ipratropium Oral Inhalation Is Used For
▾
This combination of albuterol and ipratropium treats bronchospasm in COPD.
- Combivent Respimat (inhaler): COPD in people on a regular aerosol bronchodilator who still have bronchospasm and need a second bronchodilator.
- Ipratropium Bromide and Albuterol Sulfate inhalation solution (nebulizer): bronchospasm in COPD.
How Albuterol and Ipratropium Oral Inhalation Works
▾
Albuterol activates beta-2 receptors on airway muscle, which relaxes the muscle and opens the airways. Ipratropium blocks acetylcholine at muscarinic receptors, which keeps airway muscle from tightening.
Because the two work in different ways, using them together is designed to open the airways more than either one alone. The effect is mainly local, in the lungs.
Albuterol and Ipratropium Oral Inhalation Dosage
▾
Combivent Respimat is an inhaler breathed in through the mouth. The nebulizer solution is breathed in as a mist through a jet nebulizer with a mouthpiece or face mask.
- The nebulizer solution is generally one 3 mL vial 4 times a day, with up to 2 extra doses allowed per day if needed.
- Extra doses beyond these guidelines have not been studied.
- It can be continued as medically indicated for recurring bronchospasm.
Follow your prescriber and label directions. If your usual dose stops working, get medical advice right away.
Dosing details from the FDA-approved label
From the Albuterol and Ipratropium Oral Inhalation prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Maintenance treatment of bronchospasm associated with COPD in patients requiring more than a single bronchodilator (as the label text gives the regimen for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution)
- One 3 mL vial administered 4 times per day via nebulization, with up to 2 additional 3 mL doses allowed per day, if needed
- Maximum: 4 times per day plus up to 2 additional 3 mL doses per day
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION The recommended dose of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is one 3 mL vial administered 4 times per day via nebulization with up to 2 additional 3 mL doses allowed per day, if needed. Safety and efficacy of additional doses or increased frequency of administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution beyond these guidelines has not been studied and the safety and efficacy of extra doses of albuterol sulfate or ipratropium bromide in addition to the recommended doses of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution have not been studied. The use of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution can be continued as medically indicated to control recurring bouts of bronchospasm. If a previously effective regimen fails to provide the usual relief, medical advice should be sought immediately, as this is often a sign of worsening COPD, which would require reassessment of therapy. A Pari-LC-Plus™ nebulizer (with face mask or mouthpiece) connected to a PRONEB™ compressor was used to deliver Ipratropium Bromide and Albuterol Sulfate Inhalation Solution to each patient in one U.S. clinical study. The safety and efficacy of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution delivered by other nebulizers and compressors have not been established. Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered via jet nebulizer connected to an air compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask.
Read the full Dosage and Administration section on DailyMed →
Albuterol and Ipratropium Oral Inhalation Side Effects
▾
The most common side effects with Combivent Respimat in trials were:
Common side effects
- Upper respiratory infection
- Stuffy or runny nose and sore throat (nasopharyngitis)
- Cough
- Bronchitis
- Headache
- Shortness of breath (dyspnea)
When to get medical help
- Stop the medicine and get help right away if your breathing suddenly gets worse after a dose (paradoxical bronchospasm). This can be life-threatening.
- Get emergency help for signs of a severe allergic reaction: hives, rash, swelling of the face, lips, tongue or throat, wheezing, or trouble breathing.
- Call your doctor if you notice a racing or irregular heartbeat, chest pain, or changes in blood pressure.
- If the spray gets in your eyes, contact your doctor right away for eye pain, blurred vision, halos around lights, or red eyes.
- Call your doctor if you have trouble passing urine.
- Seek help if your usual dose stops giving relief, as this can mean your COPD is worsening.
Act quickly on worsening breathing right after a dose, allergic reactions, heart effects such as a racing heartbeat, eye symptoms, or trouble urinating.
Albuterol and Ipratropium Oral Inhalation Warnings and Precautions
▾
- Paradoxical bronchospasm can be life-threatening. Stop the medicine and get help.
- Do not exceed the recommended dose. Deaths have been reported with excessive use of inhaled sympathomimetic products.
- Heart effects: albuterol can change pulse and blood pressure and cause ECG changes. Use caution with heart disease.
- Allergic reactions, including anaphylaxis, can occur.
- Eye effects: avoid spraying into the eyes. Ipratropium can worsen narrow-angle glaucoma.
- Urinary retention: caution with prostate enlargement or bladder-neck obstruction.
- Low potassium (hypokalemia) can occur and may affect the heart.
Albuterol and Ipratropium Oral Inhalation Interactions
▾
Several medicine types can clash with this combination.
- Other anticholinergics: effects can add up.
- Other sympathomimetic agents: higher risk of heart side effects.
- Beta-blockers: they and albuterol block each other.
- Non-potassium-sparing diuretics (loop or thiazide): ECG changes and low potassium can worsen.
- MAO inhibitors or tricyclic antidepressants, including within 2 weeks of stopping: albuterol's heart effects may be stronger.
Interactions listed in the FDA-approved label
From the Albuterol and Ipratropium Oral Inhalation prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications. Caution is advised in the co-administration with other drugs having anticholinergic properties.
- β-adrenergic agents (other sympathomimetic agents): There is an increased risk of adverse cardiovascular effects. Caution is advised in the co-administration with other sympathomimetic agents.
- β-receptor blocking agents: These agents and albuterol sulfate inhibit the effect of each other. Use with caution in patients with hyperreactive airways, and if used, relatively selective β1 selective agents are recommended.
- Diuretics (non-potassium sparing, such as loop or thiazide diuretics): ECG changes and/or hypokalemia that may result from non-potassium sparing diuretics can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded; the clinical significance is not known. Caution is advised in the coadministration of β-agonist-containing drugs with non-potassium sparing diuretics.
- Monoamine oxidase inhibitors or tricyclic antidepressants: The action of albuterol sulfate on the cardiovascular system may be potentiated. Administer with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents.
Read the label’s full interactions text
Drug Interactions Anticholinergic agents Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications. Caution is, therefore, advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution with other drugs having anticholinergic properties. β-adrenergic agents Caution is advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution and other sympathomimetic agents due to the increased risk of adverse cardiovascular effects. β-receptor blocking agents These agents and albuterol sulfate inhibit the effect of each other. β-receptor blocking agents should be used with caution in patients with hyperreactive airways, and if used, relatively selective β 1 selective agents are recommended. Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of β-agonist-containing drugs, such as Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, with non-potassium sparing diuretics. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular system may be potentiated.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before Taking Albuterol and Ipratropium Oral Inhalation
▾
- Do not use it with an allergy to its ingredients or to atropine or its derivatives (Combivent Respimat).
- Use caution with heart disease, narrow-angle glaucoma, enlarged prostate or bladder-neck obstruction, seizure disorders, overactive thyroid, or diabetes.
- Pregnancy: no randomized studies exist. Combivent Respimat use during labor should be limited to cases where benefit clearly outweighs risk.
- Breastfeeding: no human milk data, though levels are likely low. Discuss with your doctor.
- Children: Combivent Respimat has not been shown safe or effective, and COPD does not normally occur in children.
- Older adults: no dose adjustment of Combivent Respimat is warranted based on available data.
Albuterol and Ipratropium Oral Inhalation Overdose
▾
Overdose effects come mainly from albuterol and can include a fast or irregular heartbeat, chest pain, high or low blood pressure, tremor, nervousness, seizures, nausea, and low potassium. Cardiac arrest and death have been linked with abuse of sympathomimetic aerosols. Treatment is stopping the medicine and treating symptoms, so get emergency help.
What Albuterol and Ipratropium Oral Inhalation Does in the Body
▾
At recommended doses, ipratropium does not cause clinically significant changes in pulse or blood pressure. It did not alter mucociliary clearance or the volume or thickness of airway secretions. Inhaled albuterol can cause significant heart effects in some people, including changes in pulse, blood pressure, symptoms, or ECG.
How Your Body Processes Albuterol and Ipratropium Oral Inhalation
▾
Ipratropium's effect after inhalation is mostly local in the lungs, and much of an inhaled dose is swallowed. About 4% of a nebulized dose was excreted unchanged in urine, and the half-life after intravenous use is about 1.6 hours. Albuterol is longer acting than isoproterenol and is metabolized to albuterol 4'-O-sulfate. In the nebulizer study, albuterol reached its peak at about 0.8 hours with a half-life of roughly 7 hours. The nebulizer solution has not been studied in older adults or in people with liver or kidney problems.
How to Store Albuterol and Ipratropium Oral Inhalation
▾
PROTECT FROM LIGHT. stored in the protective foil pouch until time of use. Store at 20°C to 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Albuterol and Ipratropium Oral Inhalation: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Albuterol and Ipratropium Oral Inhalation — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
▾
How do I use it?
▾
What side effects should I expect?
▾
When should I get help right away?
▾
What if my usual dose stops working?
▾
Do I need to tell you about my other medicines?
▾
Is Albuterol and Ipratropium Oral Inhalation available over the counter?
▾
When was Albuterol and Ipratropium Oral Inhalation first available?
▾
Who makes Albuterol and Ipratropium Oral Inhalation?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More About Albuterol and Ipratropium Oral Inhalation on HelloPharmacist
Albuterol and Ipratropium Oral Inhalation Forms and Strengths (How It Comes)
Albuterol and Ipratropium Oral Inhalation is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Albuterol and Ipratropium Oral Inhalation inactive ingredients by manufacturer.
Inhalation solution (nebulizer)
How this form is used
- Ipratropium Bromide and Albuterol Sulfate inhalation solution is used to reduce bronchospasm in COPD.
- Ipratropium Bromide and Albuterol Sulfate is given by nebulization using a jet nebulizer connected to an air compressor, with a mouthpiece or suitable face mask.
- Ipratropium Bromide and Albuterol Sulfate is generally one 3 mL vial 4 times a day, with up to 2 extra doses allowed per day if needed.
- Ipratropium Bromide and Albuterol Sulfate safety and effectiveness with extra doses beyond the label guidance have not been studied.
Inhaler
How this form is used
- Combivent Respimat is used in COPD patients on a regular aerosol bronchodilator who still have bronchospasm and need a second bronchodilator.
- Combivent Respimat should not be sprayed into the eyes.
- Combivent Respimat should be stopped immediately if paradoxical bronchospasm or a serious allergic reaction occurs.
Albuterol and Ipratropium Oral Inhalation on the U.S. Market: Products, Makers and Brands
How Albuterol and Ipratropium Oral Inhalation appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
15 companies list 18 Albuterol and Ipratropium Oral Inhalation product records with the FDA, mostly as inhalation solution (nebulizer), inhaler; the earliest marketing or approval year on record is 2007. Brand names on the directory include Combivent Respimat Inhalation Spray, DuoNeb Inhalant Solution, Combivent Metered Dose Inhaler and 2 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Albuterol and Ipratropium Oral Inhalation Is Used (Medicaid Data)
A general measure of how commonly Albuterol and Ipratropium Oral Inhalation is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Albuterol and Ipratropium Oral Inhalation is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Albuterol and Ipratropium Oral Inhalation prescribed? Of the 1,603 medications we measure, Albuterol and Ipratropium Oral Inhalation ranks #146 by Medicaid prescriptions — more than 91% of them.
Utilization by Albuterol and Ipratropium Oral Inhalation product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
Other Albuterol and Ipratropium Oral Inhalation products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 22 of 43 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Albuterol and Ipratropium Oral Inhalation, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 22 of 43 listed Albuterol and Ipratropium Oral Inhalation NDCs with Medicaid activity.
Compare Albuterol and Ipratropium Oral Inhalation Products
A representative set of FDA-listed product records for Albuterol and Ipratropium Oral Inhalation — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Inhalation solution (nebulizer) | ||||
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 3 mg/3 mL | Respiratory (inhalation) | A-S Medication Solutions | ANDA | View NDC → |
| ALBUTEROL SULFATE 2.5 mg/3 mL; IPRATROPIUM BROMIDE 0.5 mg/3 mL | Respiratory (inhalation) | A-S Medication Solutions | ANDA | View NDC → |
| ALBUTEROL SULFATE 2.5 mg/3 mL; IPRATROPIUM BROMIDE 0.5 mg/3 mL | Respiratory (inhalation) | American Health Packaging | ANDA | View NDC → |
| ALBUTEROL SULFATE 2.5 mg/3 mL; IPRATROPIUM BROMIDE 0.5 mg/3 mL | Respiratory (inhalation) | Aurobindo Pharma Limited | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 3 mg/3 mL | Respiratory (inhalation) | Chartwell RX, LLC | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 2.5 mg/3 mL | Respiratory (inhalation) | Cipla USA Inc. | ANDA | View NDC → |
| ALBUTEROL SULFATE 2.5 mg/3 mL; IPRATROPIUM BROMIDE 0.5 mg/3 mL | Respiratory (inhalation) | Cipla USA Inc. | ANDA | View NDC → |
| ALBUTEROL SULFATE 2.5 mg/3 mL; IPRATROPIUM BROMIDE 0.5 mg/3 mL | Respiratory (inhalation) | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 2.5 mg/3 mL | Respiratory (inhalation) | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 3 mg/3 mL | Respiratory (inhalation) | Nephron Pharmaceuticals Corporation | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 3 mg/3 mL | Respiratory (inhalation) | Preferred Pharmaceuticals Inc. | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 2.5 mg/3 mL | Respiratory (inhalation) | Proficient Rx LP | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 3 mg/3 mL | Respiratory (inhalation) | Proficient Rx LP | ANDA | View NDC → |
| ALBUTEROL SULFATE 2.5 mg/3 mL; IPRATROPIUM BROMIDE 0.5 mg/3 mL | Respiratory (inhalation) | Redpharm Drug | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 3 mg/3 mL; ALBUTEROL SULFATE 0.5 mg/3 mL | Respiratory (inhalation) | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| ALBUTEROL SULFATE 2.5 mg/3 mL; IPRATROPIUM BROMIDE 0.5 mg/3 mL | Respiratory (inhalation) | Ritedose Pharmaceuticals, LLC | ANDA | View NDC → |
| IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 2.5 mg/3 mL | Respiratory (inhalation) | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 💊Inhaler | ||||
| IPRATROPIUM BROMIDE 20 mcg/1; ALBUTEROL SULFATE 100 mcg | Respiratory (inhalation) | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
Showing 18 of 18 products — FDA National Drug Code Directory. See every product, package size and price: browse all 18 Albuterol and Ipratropium Oral Inhalation NDCs →
Albuterol and Ipratropium Oral Inhalation Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Albuterol and Ipratropium Oral Inhalation — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Albuterol and Ipratropium Oral Inhalation in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Albuterol and Ipratropium Oral Inhalation FDA Approval History
How Albuterol and Ipratropium Oral Inhalation went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Albuterol and Ipratropium Oral Inhalation Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Albuterol and Ipratropium recalls since July 2021.
✅No Albuterol and Ipratropium recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.
Albuterol and Ipratropium Oral Inhalation Supply and Shortage Status
Whether Albuterol and Ipratropium Oral Inhalation is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Albuterol and Ipratropium Oral Inhalation Costs Pharmacies (NADAC Benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Oct 7, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Solution · Respiratory (inhalation) | 2.5; 0.5 mg/3 mL; mg/3 mL | $0.079–$0.083 per mL | NDC details & price history |
| Solution · Respiratory (inhalation) | 3; 0.5 mg/3 mL; mg/3 mL | $0.079–$0.083 per mL | NDC details & price history |
| Solution · Respiratory (inhalation) | IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 3 mg/3 mL | $0.079–$0.083 per mL | NDC details & price history |
| Solution · Respiratory (inhalation) | IPRATROPIUM BROMIDE 0.5 mg/3 mL; ALBUTEROL SULFATE 2.5 mg/3 mL | $0.079–$0.083 per mL | NDC details & price history |
| Solution · Respiratory (inhalation) | IPRATROPIUM BROMIDE 3 mg/3 mL; ALBUTEROL SULFATE 0.5 mg/3 mL | $0.079–$0.083 per mL | NDC details & price history |
| Spray, Metered · Respiratory (inhalation) | 100; 20 mcg/1; mcg | $124.16 per gram | NDC details & price history |
| Spray, Metered · Respiratory (inhalation) | IPRATROPIUM BROMIDE 20 mcg/1; ALBUTEROL SULFATE 100 mcg | $124.16 per gram | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Albuterol and Ipratropium Oral Inhalation Brand Names
Albuterol and Ipratropium Oral Inhalation is sold under 5 brand names in the FDA directory — Combivent Respimat Inhalation Spray, DuoNeb Inhalant Solution, Combivent Metered Dose Inhaler, Ipratropium Bromide and Albuterol Sulfate and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who Makes Albuterol and Ipratropium Oral Inhalation: Manufacturers and Labelers
15 companies list Albuterol and Ipratropium Oral Inhalation products with the FDA. By number of product records, the largest are A-S Medication Solutions, Cipla USA Inc., Proficient Rx LP. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Albuterol and Ipratropium Oral Inhalation Drug Class (RxNorm)
Albuterol and Ipratropium Oral Inhalation belongs to the beta2-Adrenergic Agonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for This Albuterol and Ipratropium Oral Inhalation Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Boehringer Ingelheim Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →